Insight

Aug 8, 2025, 05:47

FASCO 2025: 97 Voices, One Mission: Part 2

The title of Fellow of the American Society of Clinical Oncology (FASCO) is one of the highest honors conferred by the American Society of Clinical Oncology (ASCO). Introduced in 2007, this distinction is awarded annually to a select group of ASCO members who have demonstrated outstanding volunteer service, leadership, and commitment to ASCO’s mission.

Unlike awards based solely on academic or clinical achievements, FASCO is reserved for individuals who have made sustained, meaningful contributions to the oncology community through active involvement in ASCO programs, committees, publications, policy, and mentorship initiatives.

FASCO as a Symbol of Influence and Trust

Unlike awards focused purely on academic or clinical distinction, FASCO emphasizes organizational and community-oriented leadership. Recipients serve as trusted ambassadors for ASCO’s values shaping programs, influencing policy, and supporting the growth of the oncology workforce globally.

The 97 individuals honored in 2025 embody the critical link between clinical excellence and professional service. Their collective work reinforces ASCO’s global influence through mentorship, guideline development, educational leadership, and patient-centered advocacy.

Images	Name
	Erika P. Hamilton, MD, FASCO Director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute, Dr. Hamilton has led pivotal clinical trials in targeted therapies and immunotherapy for breast and ovarian cancers. She is a nationally recognized advocate for expanding access to cutting-edge therapies and precision oncology. Her work has directly influenced treatment paradigms and improved outcomes for patients with metastatic breast cancer.
	David N. Hayes, MD, MPH, FASCO Professor of Medicine at Duke University School of Medicine and a leading translational researcher in head and neck cancers, Dr. Hayes has made key contributions to the integration of genomics in clinical decision-making. He co-led trials that defined molecular classifications of head and neck squamous cell carcinomas and their implications in therapy response and resistance. His mentorship has shaped the next generation of clinician-scientists in oncology.
	Leslie J. Hinyard, PhD, MSW, FASCO Executive Director of the Center for Health Outcomes Research at Saint Louis University, Dr. Hinyard has led groundbreaking work on cancer disparities, health literacy, and patient-reported outcomes. With a unique background in social work and public health, she has pioneered strategies to reduce inequities in cancer care delivery and survivorship. Her research has been instrumental in shaping policy around equity-focused care.
	Richard T. Hoppe, MD, FASCO Professor Emeritus at Stanford University School of Medicine, Dr. Hoppe is a legendary figure in radiation oncology and lymphoma research. A pioneer in the use of advanced radiation techniques for Hodgkin lymphoma, he helped establish the modern standards for staging and combined-modality therapy. His decades-long career includes leadership roles in national cooperative groups and a lasting legacy of clinical excellence and mentorship.
	Yelena Y. Janjigian, MD, FASCO Chief of Gastrointestinal Oncology at Memorial Sloan Kettering Cancer Center, Dr. Janjigian is a global authority on gastroesophageal cancers. She led practice-changing trials in HER2-positive and PD-L1-positive gastric cancer and helped redefine biomarker-driven treatment. Her visionary research has transformed the management of upper GI cancers and made her a sought-after speaker and collaborator internationally.
	Komal L. Jhaveri, MD, FACP, FASCO A breast and early drug development specialist at Memorial Sloan Kettering Cancer Center, Dr. Jhaveri is recognized for her work in HER2-low and endocrine-resistant breast cancers. She has been at the forefront of trials integrating novel ADCs and CDK4/6 inhibitors, contributing to new standards of care. She is also a strong advocate for mentorship and diversity in clinical oncology leadership.
	Robin Lewis Jones, MD, MBBS, BSc, MRCP, FASCO Leader of the Sarcoma Unit at The Royal Marsden NHS Foundation Trust and Professor of Medical Oncology at the Institute of Cancer Research, London, Dr. Jones is internationally known for his work in sarcoma clinical trials and translational research. His leadership has been key in bringing innovative therapies to rare and complex soft tissue sarcomas, significantly expanding treatment options for patients worldwide.
	William Kevin Kelly, DO, FASCO Professor of Medical Oncology at Thomas Jefferson University, Dr. Kelly is a renowned genitourinary cancer expert, known for his leadership in prostate and bladder cancer research. His role in developing docetaxel-based regimens and novel androgen-targeted therapies has made a lasting impact on the field. He has also served in multiple advisory and leadership positions across cooperative groups and professional societies.
	Abhishek Kumar, MBBS, FASCO A dedicated oncologist and researcher, Dr. Kumar has contributed significantly to global oncology efforts, particularly in expanding access to clinical trials and evidence-based cancer care in low-resource settings. His advocacy for equitable care delivery, combined with his clinical excellence, has earned him recognition as an emerging leader committed to transforming global oncology landscapes.
	Lisa Y. Law, MD, FASCO An esteemed hematologist-oncologist at Kaiser Permanente, Dr. Law has made vital contributions to improving community oncology practices, particularly in supportive care and quality improvement. She has championed patient-centered models and played a pivotal role in implementing evidence-based guidelines within integrated healthcare systems, enhancing cancer outcomes across diverse populations.
	Andrew B. Lassman, MD, FASCO Chief of Neuro-Oncology at Columbia University Irving Medical Center, Dr. Lassman is a prominent figure in glioma research. He has led trials investigating temozolomide, targeted agents, and novel radiotherapeutic strategies in glioblastoma. As a mentor and educator, he has shaped neuro-oncology training and has been instrumental in developing guidelines and standards of care in CNS malignancies.
	Georgina V. Long, MD, PhD, FRACP, FASCO Co-Medical Director of Melanoma Institute Australia and Chair of Melanoma Medical Oncology and Translational Research at the University of Sydney, Professor Long is globally recognized for her landmark work in immunotherapy and targeted therapy in melanoma. Her leadership in clinical trials has transformed melanoma from a once-fatal disease into a highly treatable condition. She has received international accolades for her scientific excellence and patient advocacy.
	Martina Cathryn Murphy, MD, FASCO A gastrointestinal oncologist at the University of Florida, Dr. Murphy has distinguished herself through her dedication to patient care, education, and health equity. She has led initiatives aimed at improving access to guideline-concordant care in underserved populations and is actively involved in efforts to enhance diversity and inclusion in oncology.
	Deirdre O'Mahony, MD, FASCO Consultant Medical Oncologist at Galway University Hospital in Ireland, Dr. O'Mahony has been a leader in breast cancer research and clinical trials across Europe. She has contributed extensively to collaborative research networks and is known for her advocacy in integrating novel agents into routine care. Her clinical excellence and mentorship have strengthened oncology practice across Ireland.
	Martin Palmeri, MD, MBA, FASCO Director of the Cancer Center at Prisma Health in South Carolina, Dr. Palmeri is a dedicated oncologist and administrator who has led innovative quality improvement initiatives in cancer care delivery. His work spans both clinical excellence in gastrointestinal oncology and strategic leadership in expanding access to oncology services in community settings.
	Alberto S. Pappo, MD, FASCO Director of the Solid Tumor Division at St. Jude Children's Research Hospital, Dr. Pappo is a world-renowned leader in pediatric oncology and sarcoma research. He has been instrumental in developing new treatment protocols for rhabdomyosarcoma and rare pediatric solid tumors, significantly improving survival rates. His lifelong commitment to children with cancer is widely recognized and honored globally.
	Electra D. Paskett, PhD, MSPH, FASCO Director of the Division of Cancer Prevention and Control at The Ohio State University, Dr. Paskett is a preeminent cancer epidemiologist known for her work in cancer disparities, rural health, and community-based interventions. She has led major national studies aimed at increasing screening and prevention efforts among underserved groups. Her research has shaped public health policies and equity-focused cancer care.
	Dionisia Marie Quiroga, DO, PhD, FASCO A physician-scientist at the University of Texas MD Anderson Cancer Center, Dr. Quiroga is recognized for her contributions to precision oncology and translational research in breast cancer. Her dual training in clinical medicine and molecular biology has enabled her to lead research integrating genomic insights into patient care. She is also a passionate mentor and advocate for women in science and oncology.
	Kavitha Ramchandran, MD, FASCO Clinical Associate Professor of Medicine at Stanford University and Associate Division Chief of Medical Oncology, Dr. Ramchandran has advanced the field of thoracic oncology and health equity. Her work focuses on improving access to cancer clinical trials and incorporating patient-reported outcomes into lung cancer treatment. She is a leader in promoting inclusive care models across academic and community practices.
	Evangelia Razis, MD, PhD, FASCO Director of the Oncology Department at Hygeia Hospital in Athens, Greece, Dr. Razis is a prominent figure in global oncology and translational research. She has led major efforts to bridge molecular diagnostics with real-world care in breast and lung cancers, and her commitment to expanding research infrastructure in Europe has helped shape modern oncology in the region.
	Richard F. Riedel, MD, FASCO A medical oncologist at Duke Cancer Institute, Dr. Riedel is known for his leadership in sarcoma research and compassionate patient care. He has contributed to the development of targeted therapies and immunotherapies for soft tissue and bone sarcomas and has been a dedicated mentor and educator for early-career oncologists in rare cancers.
	Nicholas J. Robert, MD, FASCO Medical Director at US Oncology Research, Dr. Robert has played a critical role in bringing clinical trials to community oncology settings. He has led numerous multicenter studies in breast and lung cancer, helping to accelerate drug development and expand access to cutting-edge treatments for patients outside academic centers. His research and leadership have had lasting national impact.
	Tracy L. Rose, MD, FASCO A genitourinary oncologist at the University of North Carolina Lineberger Comprehensive Cancer Center, Dr. Rose is recognized for her work in clinical trials and drug development in bladder and kidney cancers. Her focus on patient-centric trial design and inclusion has led to improved therapeutic options and a more equitable research landscape.
	Abby R. Rosenberg, MD, MS, MA, FAAP, FAAHPM, FASCO Chief of Pediatric Palliative Care at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Dr. Rosenberg is a national leader in adolescent and young adult (AYA) oncology and resilience research. Her work on emotional well-being, communication, and psychosocial support has transformed standards in holistic cancer care for young patients and their families.
	Lori J. Rosenstein, MD, FASCO Hematologist-oncologist at Gundersen Health System, Dr. Rosenstein is recognized for her dedication to patient care in rural and community oncology. A champion of clinical excellence in underserved areas, she has led quality improvement projects that emphasize personalized treatment approaches and evidence-based care delivery in non-academic settings.
	Nita Louise Seibel, MD, FASCO Former Head of the Pediatric Solid Tumor Therapeutics Program at the National Cancer Institute, Dr. Seibel has been a trailblazer in pediatric oncology drug development. She played a pivotal role in launching and overseeing clinical trials for rare pediatric tumors, and her legacy includes the advancement of safer, more effective therapies for children and adolescents with cancer.
	Priyanka Sharma, MD, FASCO Professor of Medicine at the University of Kansas Medical Center and a leading breast cancer researcher, Dr. Sharma is best known for her work in triple-negative breast cancer and cancer genomics. Her leadership in biomarker-driven therapy development has helped tailor treatments for aggressive breast cancer subtypes. She also plays an active role in mentoring physician-scientists and promoting diversity in oncology research.
	Heloisa P. Soares, MD, FASCO Associate Professor at the University of Utah Huntsman Cancer Institute, Dr. Soares is a leading expert in neuroendocrine and gastrointestinal cancers. Her research has focused on rare tumors and clinical trial development, helping expand treatment options for patients with limited standard therapies. She is also a strong advocate for global oncology collaboration and mentorship in underrepresented groups.
	Walter Stadler, MD, FASCO Dean for Clinical Research and Fred C. Buffett Professor at the University of Chicago, Dr. Stadler is a renowned leader in genitourinary oncology. He has played a central role in advancing systemic therapies for kidney, bladder, and prostate cancers. A prolific investigator and mentor, Dr. Stadler has contributed to shaping both the science and structure of modern oncology clinical research.
	Latha Subramanian, MBChB, FASCO A dedicated oncologist at Minnesota Oncology, Dr. Subramanian has championed high-quality, compassionate care in community oncology settings. She has been instrumental in integrating evidence-based guidelines into routine practice and enhancing clinical trial access for patients in suburban and rural communities. Her leadership exemplifies the bridge between research and real-world care.
	Olatunji B. Alese, MD, FWACS, FASCO A gastrointestinal oncologist at Winship Cancer Institute of Emory University, Dr. Alese is recognized for his contributions to clinical trials in gastrointestinal malignancies and dedication to improving outcomes for underserved populations through patient-centered care and mentorship.
	Andrea B. Apolo, MD, FASCO As a senior investigator at the NCI and head of the bladder cancer section, Dr. Apolo has led pivotal trials in bladder and rare genitourinary cancers, advancing immunotherapy and targeted therapy in the field. She is a leading advocate for inclusion in oncology research.
	Mark A. Applebaum, MD, FASCO A pediatric oncologist at the University of Chicago, Dr. Applebaum specializes in neuroblastoma. His research integrates genomics and precision medicine to improve outcomes in childhood cancers, while he actively mentors the next generation of physician-scientists.
	Julie E. Bauman, MD, MPH, FASCO Dr. Bauman, Deputy Director of the GW Cancer Center, is a national leader in head and neck cancer and chemoprevention. Her work bridges translational science and clinical trials, and she is deeply committed to health equity and access to care.
	Sibel Blau, MD, FASCO A community oncologist and president of the Quality Cancer Care Alliance Network, Dr. Blau champions innovation in community oncology, real-world data research, and value-based care models, while mentoring women leaders in medicine.A community oncologist and president of the Quality Cancer Care Alliance Network, Dr. Blau champions innovation in community oncology, real-world data research, and value-based care models, while mentoring women leaders in medicine.
	Kristen A. Marrone, MD, FASCO A thoracic oncologist and clinical investigator at Johns Hopkins University, Dr. Marrone has led innovative research in lung cancer immunotherapy and biomarker development. She has played a key role in refining checkpoint inhibitor strategies and exploring resistance mechanisms. Her commitment to translational research continues to bridge laboratory discoveries with real-world patient care.
	Bradley Alexander McGregor, MD, FASCO A genitourinary oncology expert at Dana-Farber Cancer Institute and Harvard Medical School, Dr. McGregor has advanced the treatment landscape of kidney and bladder cancers through his work in immuno-oncology and targeted therapy trials. His collaborative research has shaped clinical decision-making in metastatic renal cell carcinoma and upper tract urothelial cancers.
	Banu Symington, MD, MACP, FASCO Medical oncologist at St. John’s Health and a longtime leader in rural oncology, Dr. Symington is admired for her commitment to improving access to cancer care in underserved regions. She has spearheaded education initiatives for community providers and contributed to the development of telemedicine-based oncology services. Her work has been pivotal in reducing geographic disparities in cancer treatment.
	Jennifer Leigh McQuade, MD, FASCO Assistant Professor at MD Anderson Cancer Center, Dr. McQuade is known for her pioneering research on the role of metabolism, the microbiome, and sex differences in melanoma. Her work on obesity and cancer immunotherapy outcomes has had significant implications for personalized cancer care. She is a strong advocate for physician-scientist training and career development.
	Umang Swami, MD, FASCO GI and GU oncology specialist at the Huntsman Cancer Institute, Dr. Swami is recognized for his contributions to early-phase clinical trials and biomarker-driven therapies in gastrointestinal cancers. He has led several innovative studies and is widely respected for his role in mentoring trainees and advocating for precision medicine in routine care.
	Eleonora Teplinsky, MD, FASCO Head of Breast Medical Oncology at Valley-Mount Sinai Comprehensive Cancer Care, Dr. Teplinsky is a prominent voice in breast cancer advocacy, clinical trial access, and patient education. She is also known for her impactful presence on social media, where she promotes science-based information and supports patient empowerment in oncology care.
	Emily Zaruhi Touloukian, DO, FASCO Dr. Touloukian is an independent community oncologist and the President and CEO of Coastal Cancer Center in Myrtle Beach, SC. In addition to being a dedicated physician, she is a strong advocate leading efforts to improve access to cancer care while providing compassionate, high-quality treatment to her patients. Her leadership and commitment to both clinical excellence and healthcare advocacy make her a powerful voice for patients and the oncology community alike.
	Jonathan C. Trent, MD, PhD, FASCO Director of the Sarcoma Medical Oncology Program at Sylvester Comprehensive Cancer Center, University of Miami, Dr. Trent is a globally respected authority on gastrointestinal stromal tumors (GIST) and sarcomas. His clinical trials and translational research have shaped current treatment paradigms, and he remains a key leader in sarcoma advocacy and education worldwide.
	Reginald Tucker-Seeley, ScD, FASCO Vice President of Health Equity at ZERO Prostate Cancer, Dr. Tucker-Seeley is a leading health disparities researcher whose work has focused on the social determinants of health in cancer care. His research has influenced national strategies to reduce inequities in cancer screening, treatment, and survivorship, particularly for men at risk for prostate cancer.
	Katherine Van Loon, MD, MPH, FASCO Director of the Global Cancer Program at UCSF Helen Diller Family Comprehensive Cancer Center, Dr. Van Loon is internationally recognized for her work in gastrointestinal cancers and global oncology. Her research addresses disparities in cancer outcomes and access to care, with a focus on implementing resource-adapted treatment strategies in low- and middle-income countries.
	Eddy Shih-Hsin Yang, MD, PhD, FASCO Chair of Radiation Oncology at the University of Mississippi Medical Center, Dr. Yang is a translational scientist and clinician known for his work on DNA repair, radiosensitization, and personalized radiation therapy. His research bridges molecular biology and clinical oncology, with a focus on breast and prostate cancers. He is a dedicated mentor and national leader in advancing precision radiation oncology.
	Oladapo O. Yeku, MD, PhD, FACP, FASCO Gynecologic medical oncologist at Massachusetts General Hospital and Harvard Medical School, Dr. Yeku is a leader in cellular immunotherapy and translational cancer research. His work on engineered T-cell therapies for ovarian and endometrial cancers is pushing the boundaries of innovation in solid tumor immunotherapy. He is also a champion for diversity in academic oncology and equitable trial participation.
	Marjorie Glass Zauderer, MD, MS, FACP, FASCO Co-Director of the Mesothelioma Program at Memorial Sloan Kettering Cancer Center, Dr. Zauderer is internationally known for her work in thoracic malignancies, particularly mesothelioma. Her leadership in early-phase and biomarker-driven clinical trials has expanded treatment options for patients with rare thoracic cancers. She also serves as a mentor and advocate for women in oncology research.
	Tian Zhang, MD, MHS, FASCO Associate Professor of Medicine at UT Southwestern Medical Center, Dr. Zhang is a rising leader in genitourinary oncology, particularly renal and bladder cancer clinical trials. She has made major contributions to defining the role of immunotherapy and biomarkers in advanced kidney cancer. Her collaborative work across cooperative groups continues to advance the field of personalized GU cancer care.
	Jeanny B. Aragon-Ching, MD, FACP, FASCO Associate Professor at George Washington University and clinical leader at the Inova Schar Cancer Institute, Dr. Aragon-Ching is widely recognized for her contributions to prostate and bladder cancer care. She has published extensively on systemic therapies and is actively involved in clinical research and professional society leadership. She is also a passionate advocate for improving oncology care in minority populations.
	Richard M. Ingram, MD, FASCO Medical oncologist at Cone Health Cancer Center in North Carolina, Dr. Ingram has championed community-based oncology research and practice transformation. He has served in leadership roles with ASCO’s Clinical Affairs Committee, helping shape quality standards and value-based care models. His dedication to advancing cancer care in non-academic settings has improved access and outcomes for thousands of patients.

Stay tuned for more global oncology updates by OncoDaily.

Written by Nare Hovhannisyan, MD

Abby R. Rosenberg Abhishek Kumar Alberto S. Pappo Andrea B Apolo Andrew B. Lassman Banu Symington Bradley Alexander McGregor cancer David N. Hayes Deirdre O'Mahony Dionisia Marie Quiroga Eddy Shih-Hsin Yang Electra D. Paskett Eleonora Teplinsky Emily Zaruhi Touloukian Erika P. Hamilton Evangelia Razis FASCO Georgina V. Long Headline Heloisa P. Soares Jeanny B. Aragon-Ching Jennifer Leigh McQuade Jonathan C. Trent Julie E. Bauman Katherine Van Loon Kavitha Ramchandran Komal L. Jhaveri Kristen A. Marrone Latha Subramanian Leslie J. Hinyard Lisa Y. Law Lori J. Rosenstein Marjorie Glass Zauderer Mark A. Applebaum Martin Palmeri Martina Cathryn Murphy Nicholas J. Robert Nita Louise Seibel Oladapo O. Yeku Olatunji B. Alese Oncology Priyanka Sharma Reginald Tucker-Seeley Richard F Riedel Richard M. Ingram Richard T. Hoppe Robin Lewis Jones Sibel Blau Tian Zhang Tracy L. Rose Umang Swami Walter Stadler William Kevin Kelly Yelena Y. Janjigian

Padraic O’Malley: Meet the Experts of VIRO 2025

Hidden Risks: BRCA Mutations and Breast Implants - CancerWorld

FDA Breakthrough Therapy Designation for Iza-bren: Advancing Treatment for EGFR-Mutant NSCLC

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Author?

LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen